Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks

The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.

Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. 

The Cardiff, UK-based company's stock surge followed the U.S. FDA granting its treatment eRapa a Fast Track designation. 

The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer. 

FAP currently has no effective medical treatment, with the only option being surgical resection of the colon or rectum.

The Fast Track designation aims to expedite the development and review of drugs targeting serious conditions with significant unmet medical needs. 

Biodexa's Phase 2 study of eRapa showed promising results, with a median 17% reduction in total polyp burden and a 75% non-progression rate at 12 months. 

In cohort 2, patients showed an even better response, with a 29% median reduction in polyp burden and an 89% non-progression rate.

On Stocktwits, retail sentiment turned 'extremely bullish,' with the stock soaring to the top 10 trending symbols. The volume of messages spiked to its highest level in a year, reflecting increased excitement among investors. 

Users were optimistic about the stock's potential, with one commenting that it could hit $10 and another suggesting that it was a "last chance to buy in before it goes above $8." 

Biodexa's stock has gained around 57% so far this year, though it is still down more than 80% over the past 12 months.

For updates and corrections, email newsroom[at]stocktwits[dot]com.<